Cargando…
Acquired resistance to daunorubicin in a patient with acute myelogenous leukaemia.
Measurement of in vitro and in vivo resistance to daunorubicin in AML patients suggests that there is no simple correlation between the two. In a patient who became clinically resistant and whose cells showed a parallel increased resistance in vitro we found the acquisition of multiple drug resistan...
Autores principales: | Smith, B. J., Kundu, D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1976
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2025136/ https://www.ncbi.nlm.nih.gov/pubmed/1066148 |
Ejemplares similares
-
Immunotherapy for Acute Myelogenous Leukaemia
por: Powles, R. L., et al.
Publicado: (1973) -
Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia.
por: Galettis, P., et al.
Publicado: (1994) -
Myelogenic Leukaemia
Publicado: (1915) -
In vitro sensitivity of clonogenic cells in resisting and relapsing patients with acute myelogenous leukaemia.
por: Marie, J. P., et al.
Publicado: (1988) -
Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis
por: Cacic, Daniel, et al.
Publicado: (2021)